LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 60

Search options

  1. Article ; Online: Real-world experience versus clinical trials: pros and cons in psoriasis therapy evaluation.

    Cinelli, Eleonora / Fabbrocini, Gabriella / Megna, Matteo

    International journal of dermatology

    2021  Volume 61, Issue 3, Page(s) e107–e108

    MeSH term(s) Humans ; Psoriasis/drug therapy
    Language English
    Publishing date 2021-05-04
    Publishing country England
    Document type Letter
    ZDB-ID 412254-9
    ISSN 1365-4632 ; 0011-9059 ; 1461-1244
    ISSN (online) 1365-4632
    ISSN 0011-9059 ; 1461-1244
    DOI 10.1111/ijd.15644
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?

    Megna, Matteo / Potestio, Luca / Fabbrocini, Gabriella / Cinelli, Eleonora

    Dermatologic therapy

    2021  Volume 34, Issue 5, Page(s) e15030

    MeSH term(s) Antibodies, Monoclonal, Humanized ; Humans ; Psoriasis/diagnosis ; Psoriasis/drug therapy ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal, Humanized ; tildrakizumab (DEW6X41BEK)
    Language English
    Publishing date 2021-06-22
    Publishing country United States
    Document type Letter
    ZDB-ID 1354801-3
    ISSN 1529-8019 ; 1396-0296
    ISSN (online) 1529-8019
    ISSN 1396-0296
    DOI 10.1111/dth.15030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison.

    Ruggiero, Angelo / Fabbrocini, Gabriella / Cinelli, Eleonora / Megna, Matteo

    Journal of the American Academy of Dermatology

    2021  Volume 85, Issue 4, Page(s) 1028–1030

    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Double-Blind Method ; Humans ; Psoriasis/drug therapy ; Severity of Illness Index ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; guselkumab (089658A12D) ; risankizumab (90ZX3Q3FR7)
    Language English
    Publishing date 2021-03-21
    Publishing country United States
    Document type Letter
    ZDB-ID 603641-7
    ISSN 1097-6787 ; 0190-9622
    ISSN (online) 1097-6787
    ISSN 0190-9622
    DOI 10.1016/j.jaad.2021.01.025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Holistic approach to psoriasis patient: What about epicardial fat tissue?

    Cinelli, Eleonora / Fabbrocini, Gabriella / Megna, Matteo

    Medical hypotheses

    2020  Volume 143, Page(s) 110123

    MeSH term(s) Adipose Tissue ; Humans ; Pericardium ; Psoriasis
    Language English
    Publishing date 2020-07-21
    Publishing country United States
    Document type Letter
    ZDB-ID 193145-3
    ISSN 1532-2777 ; 0306-9877
    ISSN (online) 1532-2777
    ISSN 0306-9877
    DOI 10.1016/j.mehy.2020.110123
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Ixekizumab in scalp psoriasis: Clinical, dermoscopical, and in vivo reflectance confocal microscopy evaluation.

    Ocampo-Garza, Sonia Sofia / Villani, Alessia / Cinelli, Eleonora / Camela, Elisa / Fabbrocini, Gabriella / Megna, Matteo

    Dermatologic therapy

    2022  Volume 35, Issue 4, Page(s) e15332

    MeSH term(s) Antibodies, Monoclonal, Humanized ; Dermoscopy ; Humans ; Microscopy, Confocal ; Psoriasis/drug therapy ; Scalp
    Chemical Substances Antibodies, Monoclonal, Humanized ; ixekizumab (BTY153760O)
    Language English
    Publishing date 2022-02-03
    Publishing country United States
    Document type Letter
    ZDB-ID 1354801-3
    ISSN 1529-8019 ; 1396-0296
    ISSN (online) 1529-8019
    ISSN 1396-0296
    DOI 10.1111/dth.15332
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Psoriasis awareness among general population: preliminary results of an online survey.

    Villani, Alessia / Cinelli, Eleonora / Fabbrocini, Gabriella / Megna, Matteo

    Italian journal of dermatology and venereology

    2021  Volume 156, Issue 6, Page(s) 665–668

    Abstract: Background: Psoriasis represents one of the most common skin diseases in Italy, with a prevalence of 2.9%. It has been defined as a noncommunicable disease, due to its high burden and impact on patients' quality of life. The aim of our observational ... ...

    Abstract Background: Psoriasis represents one of the most common skin diseases in Italy, with a prevalence of 2.9%. It has been defined as a noncommunicable disease, due to its high burden and impact on patients' quality of life. The aim of our observational study was to assess the actual knowledge and perception of psoriasis in Italian population by administering an online 10-question survey to a representative sample general population.
    Methods: An online 10-question survey was administered to a representative sample general population from September 2019 to December 2019. A representative sample of general population (age ≥18 years) was enrolled by promoting the online survey through multiple means of communication such as social sites (Facebook, Instagram) or delivering a questionnaire link in public spaces (outpatient clinic, pharmacy). All results were then collected and analyzed in graphs by the Google form platform.
    Results: One hundred fifty-one individuals participated in the survey. Results showed that 7.3% (N.=11) of general population were not familiar with the term psoriasis; 4.6% (N.=7) thought to psoriasis as an infectious disease and 6% (N.=9) thought that psoriasis was contagious. Interestingly, 39.1% (N.=59) of participants have never heard about targeted/biologic therapy. Our study is limited by the small sample size as well as lack of data regarding sex, age and education level of the study participant.
    Conclusions: There is still lack of knowledge of psoriasis among general population, representing an obstacle for patients' everyday activities and quality of life. Future studies to investigate the details of this impaired knowledge and new psoriasis campaign on large scale should fill this gap are required.
    MeSH term(s) Adolescent ; Biological Therapy ; Humans ; Prevalence ; Psoriasis/epidemiology ; Quality of Life ; Surveys and Questionnaires
    Language English
    Publishing date 2021-04-29
    Publishing country Italy
    Document type Journal Article ; Observational Study
    ZDB-ID 3065415-4
    ISSN 2784-8450
    ISSN (online) 2784-8450
    DOI 10.23736/S2784-8671.21.06822-X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.

    Ruggiero, Angelo / Fabbrocini, Gabriella / Cinelli, Eleonora / Megna, Matteo

    Dermatologic therapy

    2021  Volume 35, Issue 1, Page(s) e15214

    Abstract: IL-23-inhibitors, such as guselkumab and risankizumab, represent the newest class of biologics approved for psoriasis. Phase III trials have shown their efficacy and safety. However, real life data are still scant. to indirectly compare the effectiveness, ...

    Abstract IL-23-inhibitors, such as guselkumab and risankizumab, represent the newest class of biologics approved for psoriasis. Phase III trials have shown their efficacy and safety. However, real life data are still scant. to indirectly compare the effectiveness, safety and tolerability of guselkumab and risankizumab in real world practice. An Italian single-center retrospective cohort study enrolling moderate-to-severe psoriasis patients from September 1, 2018 and December 31, 2020 was performed to indirectly compare guselkumab and risankizumab efficacy and safety. Sixty eight patients were included (36 received guselkumab and 32 risankizumab). The groups were comparable for all analyzed characteristics, except for mean psoriasis duration (p < 0.01) which was higher for guselkumab. In guselkumab group, mean PASI reduced from 16.1 ± 6.4 (baseline) 2.1 ± 0.9 (week-28) (p < 0.001) up to 0.9 ± 0.8 (week-44) (p < 0.001). In risankizumab group mean PASI decreased from 13.5 ± 4.9 (baseline) 1.9 ± 0.8 (p < 0.001), (week-28) (p < 0.001) up to 0.9 ± 0.4 (week-40) (p < 0.001). No significant difference in mean PASI and BSA were observed between the treatments. No cases of serious AEs, injection site reaction, candida, malignancy, cardiovascular events were reported in both groups. Guselkumab and risankizumab showed favorable efficacy and safety profile, being comparable in terms of PASI90 and PASI100 responses as well as in AEs frequency and discontinuation rates.
    MeSH term(s) Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Humans ; Psoriasis/diagnosis ; Psoriasis/drug therapy ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; guselkumab (089658A12D) ; risankizumab (90ZX3Q3FR7)
    Language English
    Publishing date 2021-11-30
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1354801-3
    ISSN 1529-8019 ; 1396-0296
    ISSN (online) 1529-8019
    ISSN 1396-0296
    DOI 10.1111/dth.15214
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: A 16-year real-life study on the prevalence of mycoses in a pediatric population.

    Nocerino, Mariatresa / Cinelli, Eleonora / Megna, Matteo / Fabbrocini, Gabriella / Gallo, Lucia

    Italian journal of dermatology and venereology

    2020  Volume 156, Issue 4, Page(s) 503–504

    MeSH term(s) Child ; Humans ; Mycoses/epidemiology ; Prevalence
    Language English
    Publishing date 2020-11-12
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 3065415-4
    ISSN 2784-8450
    ISSN (online) 2784-8450
    DOI 10.23736/S2784-8671.20.06759-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Erythrasmoid pityriasis versicolor with exclusive involvement of the pubis and inguinal region.

    Cinelli, Eleonora / Vastarella, Maria / Fabbrocini, Gabriella / Gallo, Lucia

    Italian journal of dermatology and venereology

    2019  Volume 156, Issue Suppl. 1 to No. 6, Page(s) 11–12

    MeSH term(s) Abdomen ; Humans ; Pubic Bone ; Tinea Versicolor/diagnosis
    Language English
    Publishing date 2019-01-15
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 3065415-4
    ISSN 2784-8450
    ISSN (online) 2784-8450
    DOI 10.23736/S2784-8671.18.06208-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases.

    Megna, Matteo / Fabbrocini, Gabriella / Ferrillo, Maria / Cinelli, Eleonora

    Dermatologic therapy

    2020  Volume 33, Issue 6, Page(s) e14351

    Abstract: Erythrodermic psoriasis (EP) is a rare form of the disease clinically characterized by a generalized erythema covering ≥90% of the body surface area (BSA). The management of EP is challenging: no standardized guidelines exist with literature suggesting ... ...

    Abstract Erythrodermic psoriasis (EP) is a rare form of the disease clinically characterized by a generalized erythema covering ≥90% of the body surface area (BSA). The management of EP is challenging: no standardized guidelines exist with literature suggesting cyclosporine or infliximab as first-line therapy. However, a recent systematic review showed a positive response in EP patients treated with biologic agents. The most common biologic used for EP up until now has been ustekinumab, whereas infliximab might represent a first-line option in case of complicated EP (acute, severe, or unstable). Up until now, no case of brodalumab (a monoclonal antibody blocking IL-17 receptor) treatment for EP in real-life has ever been described. Here, we report the first two cases of efficacy and safety of brodalumab in real-life cases of EP.
    MeSH term(s) Antibodies, Monoclonal, Humanized ; Dermatologic Agents/adverse effects ; Humans ; Psoriasis/diagnosis ; Psoriasis/drug therapy ; Treatment Outcome ; Ustekinumab
    Chemical Substances Antibodies, Monoclonal, Humanized ; Dermatologic Agents ; brodalumab (6ZA31Y954Z) ; Ustekinumab (FU77B4U5Z0)
    Language English
    Publishing date 2020-10-10
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 1354801-3
    ISSN 1529-8019 ; 1396-0296
    ISSN (online) 1529-8019
    ISSN 1396-0296
    DOI 10.1111/dth.14351
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top